Securities and Exchange Commission

Washington, D.C. 20549

Schedule 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.)*

Phathom Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share (Title of Class of Securities)

71722W107 (CUSIP Number)

 $\label{eq:march-1} \textbf{March 1, 2023} \\ \textbf{(Date of Event Which Requires Filing of this Statement)}$

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	Names of Reporting Persons						
	The Carlyle Group Inc.						
2	Check t	he A	Appropriate Box if a Member of a Group				
	(a) 🗆		(b) □				
3	SEC U						
4	Citizen	ship	or Place of Organization				
	Delawa	ıre					
		5	Sole Voting Power				
			0				
	mber of Shares	6	Shared Voting Power				
	eficially						
Ov	vned by		2,935,106				
	Each porting	7	Sole Dispositive Power				
	Person		0				
	With	8	Shared Dispositive Power				
			2,935,106				
9	Aggreg	ate 1	Amount Beneficially Owned by Each Reporting Person				
	2,935,1	06					
10			e Aggregate Amount in Row (9) Excludes Certain Shares				
11	Not Applicable						
11	Percent	01 (Class Represented by Amount in Row 9				
	6.7%						
12	Type of	Re	porting Person				
	60						
	CO						

1	Names of Reporting Persons						
	Carlyle Holdings I GP Inc.						
2	Check t	he A	Appropriate Box if a Member of a Group				
	(a) 🗆		(b) □				
3	SEC U						
4	Citizen	ship	or Place of Organization				
	Delawa	re					
		5	Sole Voting Power				
	mber of	<u></u>	0 Shared Voting Power				
	Shares neficially	6	Shared voting Power				
	vned by		2,935,106				
	Each	7	Sole Dispositive Power				
	porting Person						
	With	8					
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	ŏ	Shared Dispositive Power				
			2,935,106				
9	Aggreg	ate 1	Amount Beneficially Owned by Each Reporting Person				
	2,935,1	06					
10			e Aggregate Amount in Row (9) Excludes Certain Shares				
	Not Applicable						
11	Percent	of (Class Represented by Amount in Row 9				
	6.7%						
12		Rej	porting Person				
	CO						

1	Names of Reporting Persons					
	Carlyle	e Ho	oldings I GP Sub L.L.C.			
2	Check t	he A	Appropriate Box if a Member of a Group			
	(a) 🗆		(b) □			
3	SEC U					
4	Citizen	ship	or Place of Organization			
	Delawa	ıre				
		5	Sole Voting Power			
Nu	mber of		0			
	Shares neficially	6	Shared Voting Power			
Ov	wned by		2,935,106			
	Each porting	7	Sole Dispositive Power			
I	Person		0			
	With	8	Shared Dispositive Power			
			2,935,106			
9	Aggreg	ate 1	Amount Beneficially Owned by Each Reporting Person			
	2,935,1	06				
10	Check i	if th	e Aggregate Amount in Row (9) Excludes Certain Shares			
	Not Applicable					
11	Percent	of (Class Represented by Amount in Row 9			
	6.7%					
12	Type of	Re	porting Person			
	OO (Limited Liability Company)					

1	Names of Reporting Persons						
	Carlyle Holdings I L.P.						
2	Check t	he A	Appropriate Box if a Member of a Group				
	(a) 🗆		(b) □				
3	SEC U						
4	Citizen	ship	or Place of Organization				
	Delawa	ıre					
		5	Sole Voting Power				
	1 (0				
	mber of Shares	6	Shared Voting Power				
_	eficially						
	vned by		2,935,106				
	Each porting	7	Sole Dispositive Power				
	Person		0				
	With	8	Shared Dispositive Power				
			2,935,106				
9	Aggreg	ate 1	Amount Beneficially Owned by Each Reporting Person				
	2,935,1	06					
10			e Aggregate Amount in Row (9) Excludes Certain Shares				
11	Not Applicable						
11	Percent of Class Represented by Amount in Row 9						
	6.7%						
12	Type of	Re	porting Person				
	PN						
	L14						

1	Names of Reporting Persons							
	CG Subsidiary Holdings L.L.C.							
2	Check t	he A	Appropriate Box if a Member of a Group					
	(a) 🗆		(b) □					
3	SEC U							
4	Citizen	ship	or Place of Organization					
	Delawa	ıre						
		5	Sole Voting Power					
Nu	mber of		0					
5	Shares	6	Shared Voting Power					
	neficially vned by		2,935,106					
	Each	7	Sole Dispositive Power					
	porting Person							
	With							
	***************************************	8	Shared Dispositive Power					
			2,935,106					
9	Aggreg	ate 1	Amount Beneficially Owned by Each Reporting Person					
	2,935,1	06						
10			e Aggregate Amount in Row (9) Excludes Certain Shares					
	Not Applicable							
11			Class Represented by Amount in Row 9					
	0.50/							
12	6.7%	. D.	neuting Develop					
12	Type of	. Ke	porting Person					
	00 (Li	mit	ed Liability Company)					

1	Names of Reporting Persons							
	TC Group, L.L.C.							
2	Check t	he A	Appropriate Box if a Member of a Group					
	(a) 🗆		(b) □					
3	SEC U	se O	nly					
4	Citizen	ship	or Place of Organization					
	Delawa	re						
		5	Sole Voting Power					
Nıı	mber of		0					
5	Shares	6	Shared Voting Power					
	neficially vned by		2,935,106					
	Each	7	Sole Dispositive Power					
	eporting Person		0					
	With	8	Shared Dispositive Power					
			2,935,106					
9	Aggreg	ate 1	Amount Beneficially Owned by Each Reporting Person					
	2,935,1	06						
10	Check i	f the	e Aggregate Amount in Row (9) Excludes Certain Shares					
	Not Applicable							
11			Class Represented by Amount in Row 9					
	6.7%							
12		Rej	porting Person					
	00 (T	mit	ed Liability Company)					
	OO (L	11111	са глаоти у Сотрану)					

1	Names of Reporting Persons					
	Carlyle	Inv	vestment Management L.L.C.			
2			Appropriate Box if a Member of a Group			
	(a) 🗆		(b) □			
3	SEC Us					
4	Citizen	ship	or Place of Organization			
	Delawa	re				
		5	Sole Voting Power			
Nun	nber of		0			
	nares eficially	6	Shared Voting Power			
Owi	ned by		2,935,106			
	Each porting	7	Sole Dispositive Power			
Pe	erson		0			
V	Vith	8	Shared Dispositive Power			
			2,935,106			
9	Aggreg	ate 1	Amount Beneficially Owned by Each Reporting Person			
	2,935,1					
10	Check i	f the	e Aggregate Amount in Row (9) Excludes Certain Shares			
	Not Applicable					
11	Percent	of (Class Represented by Amount in Row 9			
	6.7%					
12	Type of	Rej	porting Person			
	00 (Li	mit	ed Liability Company)			

1	Names of Reporting Persons						
	Carlyle Genesis UK LLC						
2	Check t	the 1	Appropriate Box if a Member of a Group				
	(a) 🗆		(b) □				
3	SEC Us	se O	nly				
4	Citizen	ship	or Place of Organization				
	Delawa	are					
		5	Sole Voting Power				
Nu	ımber of		0				
	Shares	6	Shared Voting Power				
O	neficially wned by		2,935,106				
	Each eporting	7	Sole Dispositive Power				
I	Person		0				
	With	8	Shared Dispositive Power				
			2,935,106				
9	Aggreg	ate .	Amount Beneficially Owned by Each Reporting Person				
	2,935,1						
10	10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares						
	Not Applicable						
11	Percent	of	Class Represented by Amount in Row 9				
	6.7%						
12	Type of	Re	porting Person				
	OO (Limited Liability Company)						

1	Names of Reporting Persons						
	Abingworth LLP						
2	Check t	he A	Appropriate Box if a Member of a Group				
	(a) 🗆		(b) □				
3	SEC U	se O	nly				
4	Citizen	ship	or Place of Organization				
	Englan	d aı	nd Wales				
		5	Sole Voting Power				
Nu	mber of		0				
	Shares neficially	6	Shared Voting Power				
Ov	vned by		2,935,106				
	Each porting	7	Sole Dispositive Power				
F	Person		0				
	With	8	Shared Dispositive Power				
			2,935,106				
9	Aggreg	ate 1	Amount Beneficially Owned by Each Reporting Person				
	2,935,1	06					
10	Check i	f the	e Aggregate Amount in Row (9) Excludes Certain Shares				
	Not Applicable						
11			Class Represented by Amount in Row 9				
	6.7%						
12	Type of	Rej	porting Person				
	PN						
			·				

1	Names of Reporting Persons						
	Abingworth Bioventures 8 LP						
2	Check t	the A	Appropriate Box if a Member of a Group				
	(a) 🗆		(b) □				
3	SEC Us						
4	C:::	1 .					
4	Citizen	snıp	or Place of Organization				
	Englan	d a	nd Wales				
		5	Sole Voting Power				
	1 (0				
	mber of Shares	6	Shared Voting Power				
Ben	eficially						
	vned by		1,500,000				
	Each porting	7	Sole Dispositive Power				
F	Person		0				
	With	8	Shared Dispositive Power				
			1,500,000				
9	Aggreg	ate 2	Amount Beneficially Owned by Each Reporting Person				
	1,500,0	00					
10			e Aggregate Amount in Row (9) Excludes Certain Shares				
	Not Applicable						
11	Percent of Class Represented by Amount in Row 9						
	3.4%						
12	Type of	Re	porting Person				
	PN						
	L14						

1	Names of Reporting Persons						
	Abingworth Bioventures VII LP						
2	Check t	the A	Appropriate Box if a Member of a Group				
	(a) 🗆		(b) □				
3	SEC U						
4	Citizen	ship	or Place of Organization				
	Englan	d a	nd Wales				
	-	5	Sole Voting Power				
			0				
	mber of Shares	6	Shared Voting Power				
	eficially						
	vned by		1,435,106				
	Each porting	7	Sole Dispositive Power				
	Person		0				
	With	8	Shared Dispositive Power				
			1.495.100				
9	Aggrog	ato	1,435,106 Amount Beneficially Owned by Each Reporting Person				
9	Aggreg	ate 1	Amount Beneficially Owned by Each Reporting Person				
	1,435,1	06					
10	Check i	if th	e Aggregate Amount in Row (9) Excludes Certain Shares				
	No. A Italia						
11	Not Applicable Percent of Class Represented by Amount in Row 9						
	To the state of th						
	3.3%						
12	Type of	Re	porting Person				
	PN						

ITEM 1. (a) Name of Issuer:

Phathom Pharmaceuticals, Inc. (the "Issuer").

(b) Address of Issuer's Principal Executive Offices:

100 Campus Drive, Suite 102, Florham Park, NJ 07932

ITEM 2. (a) Name of Person Filing:

Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of:

The Carlyle Group Inc.
Carlyle Holdings I GP Inc.
Carlyle Holdings I GP Sub L.L.C.
Carlyle Holdings I L.P.
CG Subsidiary Holdings L.L.C.
TC Group, L.L.C.
Carlyle Investment Management L.L.C.
Carlyle Genesis UK LLC
Abingworth LLP
Abingworth Bioventures 8 LP

(b) Address or Principal Business Office:

Abingworth Bioventures VII LP

The principal business address of each of Abingworth LLP, Abingworth Bioventures 8 LP and Abingworth Bioventures VII LP is 38 Jermyn Street, London, SW1Y 6DN, England, United Kingdom. The principal business address of each of the other Reporting Persons is c/o The Carlyle Group, 1001 Pennsylvania Ave. NW, Suite 220 South, Washington, DC 20004-2505.

(c) Citizenship of each Reporting Person is:

Each of Abingworth LLP, Abingworth Bioventures 8 LP and Abingworth Bioventures VII LP is organized under the laws of England and Wales. Each of the other Reporting Persons is organized under the laws of the State of Delaware.

(d) Title of Class of Securities:

Common Stock, par value \$0.0001 per share ("Common Stock").

(e) CUSIP Number:

71722W107

ITEM 3.

Not applicable.

ITEM 4. Ownership.

(a-c)

The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of March 1, 2023, based upon 43,605,696 shares of Common Stock outstanding, as provided by the Issuer on March 1, 2023.

Reporting Person	Amount beneficially owned	Percent of class	Sole power to vote or to direct the vote	Shared power to vote or to direct the vote	Sole power to dispose or to direct the disposition	Shared power to dispose or to direct the disposition
The Carlyle Group Inc.	2,935,106	6.7%	0	2,935,106	0	2,935,106
Carlyle Holdings I GP Inc.	2,935,106	6.7%	0	2,935,106	0	2,935,106
Carlyle Holdings I GP Sub L.L.C.	2,935,106	6.7%	0	2,935,106	0	2,935,106
Carlyle Holdings I L.P.	2,935,106	6.7%	0	2,935,106	0	2,935,106
CG Subsidiary Holdings L.L.C.	2,935,106	6.7%	0	2,935,106	0	2,935,106
TC Group, L.L.C.	2,935,106	6.7%	0	2,935,106	0	2,935,106
Carlyle Investment Management L.L.C.	2,935,106	6.7%	0	2,935,106	0	2,935,106
Carlyle Genesis UK LLC	2,935,106	6.7%	0	2,935,106	0	2,935,106
Abingworth LLP	2,935,106	6.7%	0	2,935,106	0	2,935,106
Abingworth Bioventures 8 LP	1,500,000	3.4%	0	1,500,000	0	1,500,000
Abingworth Bioventures VII LP	1,435,106	3.3%	0	1,435,106	0	1,435,106

Abingworth Bioventures 8 LP is the record holder of 1,500,000 shares of Common Stock and Abingworth Bioventures VII LP is the record holder of 1,435,106 shares of Common Stock.

The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Each of Abingworth Bioventures 8 LP and Abingworth Bioventures

VII LP has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by them. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by Abingworth Bioventures 8 LP and Abingworth Bioventures VII LP, but each disclaims beneficial ownership of such securities.

ITEM 5. Ownership of Five Percent or Less of a Class.

Not applicable.

ITEM 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

ITEM 8. Identification and Classification of Members of the Group.

Not applicable.

ITEM 9. Notice of Dissolution of Group.

Not applicable.

ITEM 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

CUSIP No. 71722W107 Schedule 13G Page 15 of 17

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: March 9, 2023

The Carlyle Group Inc.

By: /s/ Anne Frederick, attorney-in-fact

Name: Curtis L. Buser
Title: Chief Financial Officer

Carlyle Holdings I GP Inc.

y: /s/ Anne Frederick, attorney-in-fact

Name: Curtis L. Buser

Title: Managing Director and Chief Financial Officer

Carlyle Holdings I GP Sub L.L.C.

By: Carlyle Holdings I GP Inc., its sole member

By: /s/ Anne Frederick, attorney-in-fact

Name: Curtis L. Buser

Title: Managing Director and Chief Financial Officer

Carlyle Holdings I L.P.

By: /s/ Anne Frederick, attorney-in-fact

Name: Curtis L. Buser Title: Managing Director

CG Subsidiary Holdings L.L.C.

By: /s/ Anne Frederick, attorney-in-fact

Name: Curtis L. Buser Title: Managing Director

TC Group, L.L.C.

By: /s/ Anne Frederick, attorney-in-fact

Name: Curtis L. Buser Title: Managing Director CUSIP No. 71722W107 Schedule 13G Page 16 of 17

Carlyle Investment Management L.L.C.

By: /s/ Anne Frederick, attorney-in-fact

Name: Curtis L. Buser
Title: Chief Financial Officer

Carlyle Genesis UK LLC

By: Carlyle Investment Management L.L.C., its sole

member

By: /s/ Anne Frederick, attorney-in-fact

Name: Curtis L. Buser
Title: Chief Financial Officer

Abingworth LLP

By: /s/ John Heard
Name: John Heard

Title: Authorized Signatory

Abingworth Bioventures 8 LP

By: /s/ John Heard

Name: John Heard

Title: Authorized Signatory

Abingworth Bioventures VII LP

By: /s/ John Heard

Name: John Heard

Title: Authorized Signatory

LIST OF EXHIBITS

Exhibit No.	Description
24	Power of Attorney.
99	Joint Filing Agreement.

POWER OF ATTORNEY

The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Jeffrey Ferguson, Jeremy Anderson, Chintan Bhatt, Anne Frederick, Kevin Gasque, Erica Herberg, Anat Holtzman, Joshua Lefkowitz, David Lobe, Elizabeth Muscarella, Sanket Patel, Robert Rosen, and Catherine Ziobro, or any of them signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) prepare, execute in the name of each Carlyle Company and on behalf of each Carlyle Company, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of Forms D ("Form D") required to be filed in accordance with Rule 503 ("Rule 503") promulgated with respect to Sections 4(2), 4(6) and 3(b) of the Securities Act of 1933, as amended (the "1933 Act") and reports required by Sections 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended (the "1934 Act") or any rule or regulation of the SEC;
- (2) prepare and execute for and on behalf of each Carlyle Company, in the undersigned's capacity as a Chairman, authorized person, officer and/or director of each Carlyle Company, federal and state securities laws filings including without limitation Forms D pursuant to Rule 503 and Schedules 13D and 13G and Forms 3, 4, and 5 in accordance with Sections 13(d) and 16(a) of the 1934 Act and the rules thereunder;
- (3) do and perform any and all acts for and on behalf of each Carlyle Company that may be necessary or desirable to complete and execute any such federal and state securities laws filings including without limitation Forms D, Schedules 13D and 13G and Forms 3, 4, and 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and the securities administrators of any state, the District of Columbia, the Commonwealth of Puerto Rico, Guam and the United States Virgin Islands or their designees and any stock exchange or similar authority; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted, whether the same needs to be executed, taken or done by him in his capacity as a current or former member, partner, shareholder, director or officer of any company, partnership, corporation, organization, firm, branch or other entity connected with, related to or affiliated with any of the entities constituting the Carlyle Companies or entities that directly or indirectly hold interests in the Carlyle Companies.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with federal and state securities laws, including without limitation Rule 503 of the 1933 Act or Section 13 and Section 16 of the 1934 Act.

This Power of Attorney and all authority conferred hereby shall not be terminated by operation of law, whether by the death or incapacity of the undersigned or by occurrence of any other event. Actions taken by an attorney-in-fact pursuant to this Power of Attorney shall be as valid as if any event described in the preceding sentence had not occurred, whether or not the attorney-in-fact shall have received notice of such event. Notwithstanding the foregoing, (i) in the event that an attorney-in-fact is no longer employed by The Carlyle Group Employee Co., L.L.C. or its affiliates, this Power of Attorney and all authority conferred hereby shall be immediately terminated with respect to such Attorney, and (ii) the undersigned may terminate or revoke this Power of Attorney at any time.

For purposes hereof, the "Carlyle Companies" shall consist of: (i) Carlyle Group Management L.L.C., The Carlyle Group Inc., Carlyle Holdings I GP Inc., Carlyle Holdings I GP Sub L.L.C., Carlyle Holdings I L.P., TC Group, L.L.C., Carlyle Holdings II GP L.L.C., Carlyle Holdings II L.L.C., CG Subsidiary Holdings L.L.C., TC Group Investment Holdings Limited Partner L.L.C., TC Group Investment Holdings, L.P., Carlyle Holdings III GP L.P., Carlyle Holdings III L.P., TC Group Cayman L.P., TC Group Sub L.P., TC Group Investment Holdings Sub L.P., TC Group Cayman Investment Holdings Sub L.P., TC Group Cayman, L.P., TC Group Cayman Sub L.P., Five Overseas CG Investment L.L.C. and (ii) the subsidiaries and affiliates of the foregoing in clause (i), including without limitation investment funds sponsored directly or indirectly by one or more of the Carlyle Companies.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 5th day of August, 2022.

By: /s/ Curtis L. Buser

Name: Curtis L. Buser

Title: Chief Financial Officer

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 9th day of March, 2023.

The Carlyle Group Inc.

By: /s/ Anne Frederick, attorney-in-fact

Name: Curtis L. Buser Title: Chief Financial Officer

Carlyle Holdings I GP Inc.

By: /s/ Anne Frederick, attorney-in-fact

Name: Curtis L. Buser

Title: Managing Director and Chief Financial Officer

Carlyle Holdings I GP Sub L.L.C.

By: Carlyle Holdings I GP Inc., its sole member

By: /s/ Anne Frederick, attorney-in-fact

Name: Curtis L. Buser

Title: Managing Director and Chief Financial Officer

Carlyle Holdings I L.P.

By: /s/ Anne Frederick, attorney-in-fact

Name: Curtis L. Buser Title: Managing Director

CG Subsidiary Holdings L.L.C.

By: /s/ Anne Frederick, attorney-in-fact

Name: Curtis L. Buser
Title: Managing Director

TC Group, L.L.C.

By: /s/ Anne Frederick, attorney-in-fact

Name: Curtis L. Buser
Title: Managing Director

Carlyle Investment Management L.L.C.

By: /s/ Anne Frederick, attorney-in-fact

Name: Curtis L. Buser
Title: Chief Financial Officer

Carlyle Genesis UK LLC

By: Carlyle Investment Management L.L.C., its sole

member

By: /s/ Anne Frederick, attorney-in-fact

Name: Curtis L. Buser
Title: Chief Financial Officer

Abingworth LLP

/s/ John Heard

Name: John Heard

Title: Authorized Signatory

Abingworth Bioventures 8 LP

By: /s/ John Heard
Name: John Heard

Title: Authorized Signatory

Abingworth Bioventures VII LP

By: /s/ John Heard

Name: John Heard

Title: Authorized Signatory